This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Suzhou Smartnuclide Biopharmaceutical Co., Ltd.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Songbing Qin - Innovator in Biomedicine
Introduction
Songbing Qin is a prominent inventor based in Suzhou, China. He has made significant contributions to the field of biomedicine, particularly through his innovative work on PD-L1 binding polypeptides. His research focuses on the detection and diagnosis of PD-L1 related diseases, including various forms of cancer.
Latest Patents
Songbing Qin holds a patent for a PD-L1-binding polypeptide and its applications. This invention is crucial for advancing medical diagnostics and therapeutic strategies in oncology. The patent highlights the potential uses of these polypeptides in detecting and diagnosing diseases associated with PD-L1.
Career Highlights
Qin is affiliated with Suzhou Smartnuclide Biopharmaceutical Co., Ltd., where he continues to develop groundbreaking biopharmaceutical solutions. His work has positioned him as a key figure in the biomedicine sector, contributing to advancements that could improve patient outcomes.
Collaborations
He collaborates with notable colleagues, including Tao Xu and Yan Sun, who share his commitment to innovation in biomedicine. Their combined expertise enhances the research and development efforts at their company.
Conclusion
Songbing Qin's contributions to biomedicine through his patent on PD-L1 binding polypeptides exemplify the impact of innovative research in healthcare. His work continues to pave the way for advancements in cancer diagnostics and treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile